Loading...
News & Events 2017-01-11T14:32:33+00:00

Emily Whitehead Named One of Nature’s 10 People Who Mattered In Science This Year

Our co-founder Emily Whitehead has been listed among Nature's 10 people who mattered in science this year! The journal's annual list names ten people who have played a significant role in a few of the year's most impactful scientific discoveries and events. 

December 18th, 2017|News and Updates, News Release|

Oakland Raiders Jon Condo to Represent Emily Whitehead Foundation for NFL’s ‘My Cause, My Cleats’

This Sunday, December 3, Oakland Raiders long snapper Jon Condo will take to the field wearing a custom pair of cleats in support of the Emily Whitehead Foundation.

December 2nd, 2017|News and Updates|

Inaugural Emily Whitehead Foundation Believe Ball Raises $450,000

Thanks to the support of our event sponsors and all who contributed by attending, donating and participating in the silent auction and raffle, we are thrilled to announce the Believe Ball raised $450,000 in its inaugural year!

November 6th, 2017|Events, News Release|

An Update from Tom Whitehead: Meeting Gregory

Two weeks ago I received a message from parents who were at the CHOP Pediatric Intensive Care Unit. Their infant son Gregory was on the ventilator from the storm after receiving the T-cell treatment that cured Emily. We set up a call and they said that they just wanted to talk to someone who witnessed their child go through this brutal storm when the T-cells are battling the cancer.

October 26th, 2017|News and Updates|

Boston CAR-TCR Summit Raises $6k for Emily Whitehead Foundation

On September 6-7, we had the pleasure of attending the 3rd Annual CAR-TCR Summit in Boston. In partnership with the CAR-TCR Summit, the Emily Whitehead Foundation hosted a silent auction for the conference attendees and raised a total $6,000!

September 8th, 2017|News and Updates, News Release|

FDA Approves CAR-T Cell Treatment for Pediatric Patients with Acute Lymphoblastic Leukemia

This week marks a huge milestone for pediatric cancer research. The U.S. Food and Drug Administration (FDA) announced Wednesday that is has approved Novartis CAR-T cell therapy CTL019—now Kymriah—for pediatric patients with acute lymphoblastic leukemia (ALL)!

September 1st, 2017|News and Updates, News Release|